SZLS Stock Overview
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada.
Notes are coming soon
StageZero Life Sciences Ltd. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.07|
|52 Week High||CA$0.28|
|52 Week Low||CA$0.055|
|1 Month Change||16.67%|
|3 Month Change||-12.50%|
|1 Year Change||-70.21%|
|3 Year Change||-80.56%|
|5 Year Change||-94.17%|
|Change since IPO||-99.71%|
Recent News & Updates
|SZLS||CA Biotechs||CA Market|
Return vs Industry: SZLS underperformed the Canadian Biotechs industry which returned -0.2% over the past year.
Return vs Market: SZLS underperformed the Canadian Market which returned -0.4% over the past year.
|SZLS Average Weekly Movement||11.1%|
|Biotechs Industry Average Movement||10.4%|
|Market Average Movement||9.9%|
|10% most volatile stocks in CA Market||19.5%|
|10% least volatile stocks in CA Market||3.9%|
Stable Share Price: SZLS is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: SZLS's weekly volatility (11%) has been stable over the past year.
About the Company
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company’s lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer.
StageZero Life Sciences Ltd. Fundamentals Summary
|SZLS fundamental statistics|
Is SZLS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SZLS income statement (TTM)|
|Cost of Revenue||US$4.74m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.04|
|Net Profit Margin||-91.17%|
How did SZLS perform over the long term?See historical performance and comparison